Towards a paradigm shift in the treatment of chronic chagas disease

 

Autores
Viotti, Rodolfo Jorge; Alarcón de Noya, B.; Araujo Jorge, T.; Grijalva, M. J.; Guhl, F.; López, M. C.; Ramsey, J. M.; Ribeiro, I.; Schijman, Alejandro Gabriel; Sosa-estani, Sergio Alejandro; Torrico, F.; Gascon, J.; Latin American Network for Chagas Disease
Tipo de recurso
artículo
Estado
Versión publicada
Año de publicación
2014
País
Argentina
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio
CONICET Digital (CONICET)
Descripción
Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
Idioma
inglés
OAI Identifier
oai:ri.conicet.gov.ar:11336/4036
Enlace del recurso
http://hdl.handle.net/11336/4036
Nivel de acceso
Acceso abierto
Materia
CHAGAS DIASEASE
ETIOLOGICAL TREATMENT
TREATMENT EFFICACY
Medicina Tropical
Ciencias de la Salud
CIENCIAS MÉDICAS Y DE LA SALUD